1846.Hk
1846.HK operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through product sales and service provision.
Business. 1846.HK operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through product sales and service provision.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
1846.HK operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through product sales and service provision.
The company maintains a strong liquidity position, with a current ratio of 2.79, indicating that it has more than enough current assets to cover its current liabilities. Additionally, the company holds significant cash and equivalents of HKD 695.54 million, which further supports its liquidity and financial flexibility.
In terms of profitability, the company's return on equity (ROE) is 4.36%, and its return on assets (ROA) is 2.79%. These figures are below the industry median for ROE and ROA, suggesting that the company is not generating returns as efficiently as its peers. The net income of HKD 54.45 million indicates a modest profit, but the operating income of HKD 114.63 million suggests that the company is managing its operating costs relatively well.
The company's revenue is concentrated in a single segment, as no specific segments are disclosed in the available data. The geographic exposure is not detailed, but the company's operations are primarily based in Hong Kong, as indicated by the ticker symbol and the currency used in financial reporting.
The company's growth trajectory is modest, with a revenue of HKD 796.04 million in the latest reporting period. The outlook for the current fiscal year is not explicitly provided, but the company's historical revenue performance suggests a stable, if not aggressive, growth pattern. The company's net income and operating income have shown a consistent trend, indicating a stable financial performance.
The risk assessment indicates a low level of liquidity and dilution risk. The company's debt-to-equity ratio of 0.33 suggests a conservative capital structure, with a relatively low amount of debt compared to equity. There are no immediate filing-based liquidity or dilution flags, indicating that the company is not currently facing significant financial risks.
Recent events and filings do not show any significant changes in the company's financial or operational status. The latest actual EPS is 0.03 HKD, and the latest actual revenue is 84,798,000 HKD, as reported by analysts.
- The company has a strong liquidity position with a current ratio of 2.79 and significant cash reserves.
- The company's profitability metrics, such as ROE and ROA, are below the industry median, indicating less efficient returns.
- The company's revenue is concentrated in a single segment, and geographic exposure is primarily in Hong Kong.
- The company's growth trajectory is modest, with stable financial performance and no significant financial risks identified.
- "margin_outlook_rationale": "The company's margin outlook is stable, supported by consistent operating income and a conservative capital structure.",
- "rd_outlook_rationale": "The company's R&D outlook is not explicitly detailed, but the stable financial performance suggests ongoing investment in innovation.",
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Return On Assetsnet_income / total_assets
- 1846.HK Market data — financials · 2026-05-26
- Euroeyes International Eye Clinic Ltd Market data — analyst estimates · 2026-05-26